Skip to content
2000
image of Approaches in Skin Cancer Management: Treatment, Early Detection, and Patient-Centric Therapies

Abstract

Skin cancer is the most common cancer globally, and BCCs and CSCCs do comprise most of the non-melanoma skin cancer. The review summarises new epidemiological evidence (2020-2025), indicating the dynamics in global incidence, long-term WHO forecasts to 2050 and the interaction of genes and the environment as risk factors. Pathophysiological understanding highlights molecular modulations, escape from immune attack and the effects of chronic ultraviolet exposure on the development of tumours. The causes and mechanisms of action section has been reorganised and includes detailed mechanistic descriptions of current treatment modalities, such as surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy, with examples of clinical applications. Particular emphasis is laid on the clinical treatment of BCC and CSCC in the older adult population, with references to the latest international guidelines and consideration of psychological and social support in treating patients. The new treatment methods emerging, like nanocarrier, photodynamic therapy, and personalised medicine, are addressed with the recent data on their application and future outlook. Under the new section of prevention and patient education, there is an outline of community awareness programs, campaigns aimed at reducing the burden of the sun, early detection, and evidence-based approaches to reduce the disease burden. Other approaches in technical methods are also reviewed to determine their translational opportunities, comprising hyaluronic acid delivery methods, ultrasonic-assisted nanoparticle penetration, and microneedle technology. Current publications have been used massively, and they constitute more than 50 percent of the provided circulatory content, with publications from the last five years, which adds to their clinical nature and timeliness. Bringing together current epidemiology, new treatment approaches, and patient-focused prevention, this review presents a complete evidence-based source to assist clinicians, researchers, and public health staff in managing the emerging era of skin cancer treatment.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128413392251126055554
2026-02-26
2026-03-07

  • From This Site

    /content/journals/cpd/10.2174/0113816128413392251126055554
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Olsen C.M. Wilson L.F. Green A.C. Prevention of skin cancer: An epidemiological review of evidence-based interventions. J. Clin. Oncol. 2022 40 24 2702 2713 10.1200/JCO.22.00245
    [Google Scholar]
  2. Wang M. Gao X. Zhang L. Recent global patterns in skin cancer incidence, mortality, and prevalence. Chin. Med. J. 2025 138 2 185 192 10.1097/CM9.0000000000003416 39682020
    [Google Scholar]
  3. Aggarwal P. Knabel P. Fleischer A.B. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. J. Am. Acad. Dermatol. 2021 85 2 388 395 10.1016/j.jaad.2021.03.109 33852922
    [Google Scholar]
  4. Silva E.S. Tavares R. Paulitsch F. Sunscreen use and skin cancer prevention: Systematic review and meta-analysis. Cancers 2023 15 24 5868 10.3390/cancers15245868 38136411
    [Google Scholar]
  5. Goyal R. Husain S. Wilson K. Recent advancements in skin cancer treatment: A critical review. Explor. Med. 2023 4 782 812 10.37349/emed.2023.00178
    [Google Scholar]
  6. Dobbinson S. Wakefield M. Jamsen K. Assessing the benefits of the SunSmart program: Cost-effectiveness and impact on skin cancer rates in Australia. Aust. N. Z. J. Public Health 2021 45 5 483 490 10.1111/1753‑6405.13127
    [Google Scholar]
  7. Hasan N. Nadaf A. Imran M. Skin cancer: Understanding the journey of transformation from conventional to advanced treatment approaches. Mol. Cancer 2023 22 1 168 10.1186/s12943‑023‑01854‑3 37803407
    [Google Scholar]
  8. Alam M. Armstrong A. Baum C. Guidelines of care for managing cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol. 2018 78 3 560 578 10.1016/j.jaad.2017.10.007 29331386
    [Google Scholar]
  9. Peris K. Fargnoli M.C. Garbe C. Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines. Eur. J. Cancer 2019 118 10 34 10.1016/j.ejca.2019.06.003 31288208
    [Google Scholar]
  10. Piña-Sánchez P. Chávez-González A. Ruiz-Tachiquín M. Cancer biology, epidemiology, and treatment in the 21st century: Current status and future challenges from a biomedical perspective. Cancer Contr. 2021 28 10732748211038735 10.1177/10732748211038735 34565215
    [Google Scholar]
  11. Heistein J.B. Acharya U. Mukkamalla S.K.R. Malignant Melanoma. Treasure Island, FL StatPearls Publishing 2025
    [Google Scholar]
  12. Perissinotti A. Rietbergen D.D.D. Vidal-Sicart S. Riera A.A. Olmos R.A.V. Melanoma & nuclear medicine: New insights & advances. Melanoma Manag. 2018 5 1 MMT06 10.2217/mmt‑2017‑0022 30190932
    [Google Scholar]
  13. Lakshmi S. Singh S. Shah K. Dewangan H.K. Dual Vinorelbine bitartrate and Resveratrol loaded polymeric aqueous core nanocapsules for synergistic efficacy in breast cancer. J. Microencapsul. 2022 39 4 299 313 10.1080/02652048.2022.2070679 35470755
    [Google Scholar]
  14. Ciuciulete A.R. Stepan A.E. Andreiana B.C. Simionescu C.E. Non-melanoma skin cancer: Statistical associations between clinical parameters. Curr. Health Sci. J. 2022 48 1 110 115 10.12865/CHSJ.48.01.16 35911940
    [Google Scholar]
  15. Narayanan D.L. Saladi R.N. Fox J.L. Ultraviolet radiation and skin cancer. Int. J. Dermatol. 2022 61 7 799 814 10.1111/ijd.15930 20883261
    [Google Scholar]
  16. Marzuka A.G. Book S.E. Basal cell carcinoma: Pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J. Biol. Med. 2019 92 1 35 41 26029015
    [Google Scholar]
  17. Sharma A.N. Upadhyay P.K. Dewangan H.K. Development, evaluation, pharmacokinetic and biodistribution estimation of resveratrol-loaded solid lipid nanoparticles for prostate cancer targeting. J. Microencapsul. 2022 39 6 563 574 10.1080/02652048.2022.2135785 36222429
    [Google Scholar]
  18. Teng Y Yu Y Li S Ultraviolet radiation and basal cell carcinoma: An environmental perspective. Front Public Health 2021 9 666528 10.3389/fpubh.2021.666528 34368047
    [Google Scholar]
  19. Pei M. Wiefels M. Harris D. Perineural invasion in head and neck cutaneous squamous cell carcinoma. Cancers 2024 16 21 3695 10.3390/cancers16213695 39518134
    [Google Scholar]
  20. Fania L. Didona D. Di Pietro F.R. Cutaneous squamous cell carcinoma: From pathophysiology to novel therapeutic approaches. Biomedicines 2021 9 2 171 10.3390/biomedicines9020171 33572373
    [Google Scholar]
  21. Yadav D. Semwal B.C. Dewangan H.K. Grafting, characterization, and enhancement of therapeutic activity of berberine-loaded PEGylated PAMAM dendrimer for cancer cells. J. Biomater. Sci. Polym. Ed. 2022 14 1 14 10.1080/09205063.2022.2155782 36469754
    [Google Scholar]
  22. Karia P.S. Han J. Schmults C.D. Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J. Am. Acad. Dermatol. 2019 80 4 1036 1042 10.1016/j.jaad.2018.11.037 23375456
    [Google Scholar]
  23. Thompson A.K. Kelley B.F. Prokop L.J. Murad M.H. Baum C.L. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: A systematic review and meta-analysis. JAMA Dermatol. 2016 152 4 419 428 10.1001/jamadermatol.2015.4994 26762219
    [Google Scholar]
  24. Kricker A. Armstrong B.K. Hughes A.M. Goumas C. Fritschi L. Risk of basal cell carcinoma and squamous cell carcinoma of the skin in relation to chronic occupational exposure to solar UVR. Br. J. Dermatol. 2018 179 3 636 644 10.1111/bjd.16571
    [Google Scholar]
  25. Leiter U. Keim U. Garbe C. Epidemiology of skin cancer: Update 2020. Adv. Exp. Med. Biol. 2020 1268 123 139 10.1007/978‑3‑030‑46227‑7_6 32918216
    [Google Scholar]
  26. Pandeya N. Olsen C.M. Thompson B.S. Dusingize J.C. Neale R.E. Etiology of cutaneous squamous cell carcinoma: Insights from genetic epidemiology. J. Invest. Dermatol. 2021 141 4 789 797 10.1016/j.jid.2020.08.018
    [Google Scholar]
  27. Olsen C.M. Thompson B.S. Pandeya N. Risk factors for basal cell carcinoma and squamous cell carcinoma in a population-based cohort: Results from the QSkin Study. J. Invest. Dermatol. 2021 141 9 2108 2116 10.1016/j.jid.2020.11.027
    [Google Scholar]
  28. Marwah H. Pant J. Yadav J. Shah K. Dewangan H.K. Biosensor detection of COVID-19 in lung cancer: Hedgehog and mucin signaling insights. Curr. Pharm. Des. 2023 29 43 3442 3457 10.2174/0113816128276948231204111531 38270161
    [Google Scholar]
  29. Olsen C.M. Green A.C. Neale R.E. Nevus phenotype and the risk of melanoma: A pooled analysis from the International Melanoma Genetics Consortium (GenoMEL). Int. J. Cancer 2020 146 5 1206 1215 10.1002/ijc.32471
    [Google Scholar]
  30. DeWane M.E. Kelsey A. Oliviero M. Melanoma epidemiology, biology, and prognosis. Treasure Island, FL StatPearls 2023
    [Google Scholar]
  31. Rallis E. Gregoriou S. Rigopoulos D. Advances in topical therapies for non-melanoma skin cancer. Curr. Pharm. Des. 2020 26 36 4565 4574 10.2174/1381612826666200707205117
    [Google Scholar]
  32. Sharma A.N. Dewangan H.K. Upadhyay P.K. Comprehensive review on herbal medicine: Emphasis on current therapy and role of phytoconstituents for cancer treatment. Chem. Biodivers. 2024 21 3 202301468 10.1002/cbdv.202301468 38206170
    [Google Scholar]
  33. Sharma A.N. Upadhyay P.K. Dewangan H.K. Dual combination of resveratrol and pterostilbene aqueous core nanocapsules for integrated prostate cancer targeting. Ther. Deliv. 2024 15 9 685 698 10.1080/20415990.2024.2380239 39129676
    [Google Scholar]
  34. Buja A. Rugge M. Trevisiol C. Cutaneous melanoma in older patients. BMC Geriatr. 2024 24 1 232 10.1186/s12877‑024‑04806‑8 38448833
    [Google Scholar]
  35. Batista C. Bastos V. Oliveira H. Emerging nanocarrier platforms for skin cancer therapy. J. Nanobiotechnology 2022 20 1 269 10.1186/s12951‑022‑01491‑2 35690818
    [Google Scholar]
  36. Shreberk-Hassidim R. Ostrowski S.M. Fisher D.E. The complex interplay between nevi and melanoma: Risk factors and precursors. Int. J. Mol. Sci. 2023 24 4 3541 10.3390/ijms24043541 36834954
    [Google Scholar]
  37. He Z. Zhang S. Song Q. Photodynamic therapy for skin cancer: Recent advances and future perspectives. Cancer Lett. 2020 470 141 155 10.1016/j.canlet.2019.10.026
    [Google Scholar]
  38. Marwah H. Dewangan H.K. Advancements in solid lipid nanoparticles and nanostructured lipid carriers for breast cancer therapy. Curr. Pharm. Des. 2024 30 37 2922 2936 10.2174/0113816128319233240725103706 39150028
    [Google Scholar]
  39. Garcovich S. Colloca G. Sollena P. Skin cancer epidemics in the elderly as an emerging issue in geriatric oncology. Aging Dis. 2017 8 5 643 661 10.14336/AD.2017.0503 28966807
    [Google Scholar]
  40. Khayyati Kohnehshahri M. Sarkesh A. Mohamed Khosroshahi L. Current status of skin cancers with a focus on immunology and immunotherapy. Cancer Cell Int. 2023 23 1 174 10.1186/s12935‑023‑03012‑7 37605149
    [Google Scholar]
  41. Eggermont A.M.M. Blank C.U. Mandalà M. Adjuvant pembrolizumab versus placebo in resected stage IIB or IIC melanoma. N. Engl. J. Med. 2022 387 23 2113 2124 10.1056/NEJMoa2212073 36477031
    [Google Scholar]
  42. Stratigos A.J. Garbe C. Dessinioti C. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur. J. Cancer 2020 128 83 102 10.1016/j.ejca.2020.01.008 32113942
    [Google Scholar]
  43. a Lansbury L. Bath-Hextall F. Perkins W. Stanton W. Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: Systematic review and pooled analysis of observational studies. BMJ 2013 347 f6153 10.1136/bmj.f6153 24191270
    [Google Scholar]
  44. b Kim J.Y.S. Kozlow J.H. Mittal B. Moyer J. Olenecki T. Rodgers P. Guidelines of care for the management of cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol. 2018 78 3 560 578 10.1016/j.jaad.2017.10.007 29331386
    [Google Scholar]
  45. Robert C. Long G.V. Brady B. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2021 384 11 1026 1036 10.1056/NEJMoa2109328 25399552
    [Google Scholar]
  46. Que S.K.T. Zwald F.O. Schmults C.D. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors. J. Am. Acad. Dermatol. 2020 83 1 123 136 10.1016/j.jaad.2020.01.072 32165196
    [Google Scholar]
  47. Sharma N. Bhati A. Aggarwal S. Shah K. Dewangan H.K. PARP pioneers: Using BRCA1/2 mutation-targeted inhibition to revolutionize breast cancer treatment. Curr. Pharm. Des. 2025 31 9 663 673 10.2174/0113816128322894241004051814 39421986
    [Google Scholar]
  48. Morton C.A. Szeimies R.M. Basset-Seguin N. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: Treatment delivery and established indications – Actinic keratoses, Bowen’s disease and basal cell carcinomas. J. Eur. Acad. Dermatol. Venereol. 2019 33 12 2225 2238 10.1111/jdv.16017 31779042
    [Google Scholar]
  49. Venables Z.C. Nijsten T. Wong K.F. Epidemiology of basal and cutaneous squamous cell carcinoma in the UK 2013–2018: A cohort study. Br. J. Dermatol. 2021 184 1 90 98 10.1111/bjd.19180
    [Google Scholar]
  50. Li X. Xie J. Zhang H. Advances in targeted therapy for skin cancer. Front. Pharmacol. 2022 13 832548 10.3389/fphar.2022.832548
    [Google Scholar]
  51. Wang Y. Wang L. Xu J. Advances in the treatment of skin cancer using photothermal therapy. Int. J. Nanomedicine 2021 16 5189 5205 10.2147/IJN.S322015
    [Google Scholar]
  52. Saladi R.N. Persaud A.N. Phelps R.G. Epidemiology of skin cancer in the 21st century. Clin. Dermatol. 2022 40 5 571 580 10.1016/j.clindermatol.2022.05.001
    [Google Scholar]
  53. Robert C. Ribas A. Schachter J. Pembrolizumab versus ipilimumab in advanced melanoma. Lancet 2021 398 10304 308 318 10.1016/S0140‑6736(21)01317‑8
    [Google Scholar]
  54. Dewangan H.K. Sharma R. Shah K. Vadaga A.K. Veer M. Alam P. Optimisation and evaluation of long-circulating Ru-SLN carrier for targeting melanoma cells. J. Microencapsul. 2024 1 13 39718466
    [Google Scholar]
  55. Olsen C.M. Green A.C. Whiteman D.C. Trends in skin cancer incidence by age and gender: A global review. Curr. Opin. Oncol. 2023 35 2 125 133 10.1097/CCO.0000000000000925 36633319
    [Google Scholar]
  56. Zhao H. Zhang J. Ma W. Tislelizumab for treatment of advanced melanoma: A multicenter, phase III trial. Lancet Oncol. 2021 22 9 1254 1264 10.1016/S1470‑2045(21)00355‑9
    [Google Scholar]
  57. Dwiyana R.F. Gondokaryono S.P. Rahardja J.I. Clinical efficacy of dialkylcarbamoylchloride-coated cotton acetate dressing versus combination of normal saline dressing and 2% mupirocin ointment in infected wounds of epidermolysis bullosa. Dermatol. Ther. 2019 32 5 e13047 10.1111/dth.13047
    [Google Scholar]
  58. Baba P.U.F. Hassan A. Khurshid J. Wani A.H. Basal cell carcinoma: Diagnosis, management and prevention. J Mol Pathol 2024 5 2 153 170 10.3390/jmp5020010
    [Google Scholar]
  59. Natelauri E. Jghamadze A. Radiation Therapy for Basal Cell Skin CancerSkin Cancer - Past, Present and Future. IntechOpen 2025
    [Google Scholar]
  60. Marwah H. Dewangan H.K. Pterostilbene as a potent ESR-1 in breast cancer therapy: Insights from network pharmacology, molecular docking, dynamics simulations, ADMET, and in vitro analysis. Mol. Divers. 2025 1 19 10.1007/s11030‑025‑11144‑3 39992538
    [Google Scholar]
  61. Paoli J. Dahlén Gyllencreutz J. Fougelberg J. Nonsurgical options for the treatment of basal cell carcinoma. Dermatol. Pract. Concept. 2019 9 2 75 81 10.5826/dpc.0902a01 31106008
    [Google Scholar]
  62. Requena C. Nagore E. Traves V. Management of locally advanced and metastatic basal cell carcinoma: Real-world data. Acta Derm. Venereol. 2019 99 12 1092 1096 10.2340/00015555‑3306
    [Google Scholar]
  63. Marwah H. Dewangan H.K. Synergistic targeting of EGFR, ESR1, BCL2, and TP53 pathways: A multi-pronged approach for advanced breast cancer therapy. Curr. Cancer Drug Targets 2025 25 10.2174/0115680096366956250314043513 40277116
    [Google Scholar]
  64. Stratigos A.J. Garbe C. Lebbe C. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur. J. Cancer 2020 128 83 102 10.1016/j.ejca.2020.01.008 32113942
    [Google Scholar]
  65. Ewii U.E. Onugwu A.L. Nwokpor V.C. Novel drug delivery systems: Insight into self-powered and nano-enabled drug delivery systems. Nano TransMed 2024 3 100042 10.1016/j.ntm.2024.100042
    [Google Scholar]
  66. Ezike T.C. Okpala U.S. Onoja U.L. Advances in drug delivery systems, challenges and future directions. Heliyon 2023 9 6 17488 10.1016/j.heliyon.2023.e17488 37416680
    [Google Scholar]
  67. Basal Cell Skin Cancer 2024 Available from: https://www.nccn.org
  68. Chandel R.S. Dewangan H.K. Cancer drug targeting: Molecular mechanism, approaches, and regulatory framework. Curr. Pharm. Des. 2025 31 22 1767 1780 10.2174/0113816128364722250126172914 39957701
    [Google Scholar]
  69. Brinker T.J. Hekler A. Utikal J.S. Skin cancer classification using convolutional neural networks: Systematic review. J. Med. Internet Res. 2018 20 10 11936 10.2196/11936 30333097
    [Google Scholar]
  70. Ozdemir B. Pacal I. An innovative deep learning framework for skin cancer detection employing ConvNeXtV2 and focal self-attention mechanisms. Results Eng. 2025 25 103692 10.1016/j.rineng.2024.103692
    [Google Scholar]
  71. Dewangan H.K. Sharma R. Shah K. Alam P. Development of FA-conjugated PAMAM dendrimer as potential antioxidant therapy for cancer cells. J. Mater. Res. 2025 40 9 1405 1416 10.1557/s43578‑025‑01587‑7
    [Google Scholar]
  72. Marwah H. Pant J. Shah K. Alam P. Dewangan H.K. Anticancer efficacy of dual-loaded SLNs with Doxorubicin (DOX) and Pterostilbene (PTS): Formulation, characterization, and evaluation for breast cancer. Nanomedicine 2025 20 11 1249 1265 10.1080/17435889.2025.2501526 40328655
    [Google Scholar]
  73. Bichakjian C.K. Olencki T. Aasi S.Z. Basal cell carcinoma, version 2.2022, NCCN guidelines. J. Natl. Compr. Canc. Netw. 2022 20 5 503 529 10.6004/jnccn.2022.0022
    [Google Scholar]
  74. Venables Z.C. Autier P. Nijsten T. Incidence trends of keratinocyte cancers in Europe. Br. J. Dermatol. 2020 183 6 1043 1050 10.1111/bjd.19132
    [Google Scholar]
  75. Zhang M. Gao S. Yang D. Influencing factors and strategies of enhancing nanoparticles into tumors in vivo. Acta Pharm. Sin. B 2021 11 8 2265 2285 10.1016/j.apsb.2021.03.033 34522587
    [Google Scholar]
  76. Pant J. Marwah H. Mittal P. Singh L. Dewangan H.K. Protective effects of valencene, a natural sesquiterpene, against benzo(a)pyrene-induced lung cancer in Swiss albino mice. Med. Oncol. 2025 42 9 393 10.1007/s12032‑025‑02962‑4 40736625
    [Google Scholar]
  77. Soura E. Geller A.C. Tsao H. Skin cancer: Risk factors, prevention, and early detection. Semin. Oncol. Nurs. 2020 36 5 151069 10.1016/j.soncn.2020.151069 33012610
    [Google Scholar]
  78. Erikson K. Brosig A. Zimbelmann M.W. Alternative treatment options for periocular basal cell carcinoma: A narrative review. Front. Oral Maxillofac. Med. 2022 4 25 5 10.21037/fomm‑21‑19
    [Google Scholar]
  79. Workman A. Velangi S. Hill D. Advances in immunotherapy for non-melanoma skin cancer. Clin. Exp. Dermatol. 2021 46 8 1358 1366 10.1111/ced.14794
    [Google Scholar]
  80. Rudari M. Brooks R. Dragu A. Alawi S.A. A comparison between national and international melanoma skin cancer treatment guidelines. Clin. Dermatol. 2025 43 1 24 28 10.1016/j.clindermatol.2025.01.011 39922435
    [Google Scholar]
  81. Schmults C.D. Blitzblau R. Aasi S.Z. NCCN guidelines insights: Squamous cell skin cancer, version 2.2022. J. Natl. Compr. Canc. Netw. 2022 20 6 653 663 10.6004/jnccn.2022.0025 35231901
    [Google Scholar]
  82. Amjadi M. Sheervalilou R. Karami Z. Iontophoresis for the cutaneous delivery of nanoencapsulated drugs. Drug Dev. Ind. Pharm. 2020 46 7 1099 1110 10.1080/03639045.2020.1738283
    [Google Scholar]
  83. Meeuwis K. Bavinck J.N. Euvrard S. Prevention and management of skin cancer in organ transplant recipients: European consensus statements. J. Am. Acad. Dermatol. 2021 84 3 629 637 10.1016/j.jaad.2020.05.138
    [Google Scholar]
  84. Hegde U.P. Kumar P. Haroon R. Smart nanocarriers for targeted skin cancer therapy: Advances and perspectives. Mater. Sci. Eng. C 2021 126 112160 10.1016/j.msec.2021.112160
    [Google Scholar]
  85. Fallacara A. Baldini E. Manfredini S. Vertuani S. Hyaluronic acid in the third millennium. Polymers 2018 10 7 701 10.3390/polym10070701 30960626
    [Google Scholar]
  86. Zhao Y. Li Y. Wang Z. Hyaluronic acid-based drug delivery systems for cancer therapy. Int. J. Biol. Macromol. 2020 152 1094 1109 10.1016/j.ijbiomac.2019.10.186
    [Google Scholar]
  87. Huang G. Huang H. Application of hyaluronic acid as carriers in drug delivery. Drug Deliv. 2018 25 1 766 772 10.1080/10717544.2018.1450910 29536778
    [Google Scholar]
  88. Zhou Q. Zhang L. Wu H. Ultrasound-mediated drug delivery for cancer therapy: A review. Ultrason. Sonochem. 2020 62 104901 10.1016/j.ultsonch.2019.104901
    [Google Scholar]
  89. Curiel L. Chopra R. Hynynen K. Focused ultrasound for cancer therapy. Phys. Med. Biol. 2020 65 2 02TR01 10.1088/1361‑6560/ab5d53 31694009
    [Google Scholar]
  90. Zhao Z. Ukidve A. Kim J. Mitragotri S. Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer’s disease. Adv. Drug Deliv. Rev. 2020 165-166 68 85 10.1016/j.addr.2019.09.001
    [Google Scholar]
  91. Larrañeta E. Lutton R.E. Woolfson A.D. Donnelly R.F. Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development. Mater. Sci. Eng. Rep. 2018 137 1 33 10.1016/j.mser.2018.01.001
    [Google Scholar]
  92. Larrañeta E. Moore J. Vicente-Pérez E.M. A proposed model membrane and test method for microneedle insertion studies. Int. J. Pharm. 2018 547 1-2 123 129 10.1016/j.ijpharm.2018.05.044 30130604
    [Google Scholar]
  93. Nguyen T.T. Tran T. Banga A.K. Enhanced skin delivery of vismodegib using microneedles. Drug Deliv. Transl. Res. 2021 11 5 2026 2036 10.1007/s13346‑020‑00888‑1
    [Google Scholar]
  94. Li D. Martini L.G. Ford J.L. Roberts M. The use of microneedle arrays for transdermal drug delivery. J. Control. Release 2022 349 124 140 10.1016/j.jconrel.2022.06.027
    [Google Scholar]
  95. a Ripolin A. Quinn J. Larrañeta E. Vicente-Pérez E.M. Barry J. Donnelly R.F. Successful application of large microneedle patches by human volunteers. Int. J. Pharm. 2017 521 1-2 92 10.1016/j.ijpharm.2017.02.011 28216463
    [Google Scholar]
  96. b Ita K. Perspectives on transdermal electroporation. Pharmaceutics 2016 8 1 9 10.3390/pharmaceutics8010009 26999191
    [Google Scholar]
  97. a Ita K. Transdermal delivery of drugs with microneedles-potential and challenges. Pharmaceutics 2015 7 3 90 105 10.3390/pharmaceutics7030090 26131647
    [Google Scholar]
  98. b Donnelly R.F. Raj Singh T.R. Woolfson A.D. Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety. Drug Deliv. 2010 17 4 187 207 10.3109/10717541003667798 20297904
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128413392251126055554
Loading
Approaches in Skin Cancer Management: Treatment, Early Detection, and Patient-Centric Therapies
Bentham Science Publishers ; https://doi.org/10.2174/0113816128413392251126055554
/content/journals/cpd/10.2174/0113816128413392251126055554
/content/journals/cpd/10.2174/0113816128413392251126055554
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: squamous cell carcinoma ; basal cell carcinoma ; Skin cancer ; treatment approaches ; chemotherapy ; nano transporters

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test